CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BenevolentAI SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BenevolentAI SA
4-8 Maple Street
LONDON, W1T 5HD  United Kingdom Ticker: BAIBAI

This company was Merged or Acquired on 4/22/2022.
This is a Subsidiary, click here for the Parent Company

Business Summary
BenevolentAI SA is an artificial intelligence (AI)-enabled drug discovery and development company. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, it delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers its in-house drug pipeline and supports collaborations with AstraZeneca, as well as research and charitable institutions. Its pipeline includes BEN-2293, BEN-8744, BEN-9160 and BEN-28010. It integrates data from across domains and data types, including omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology. BEN-8744 is under development as an ulcerative colitis treatment for a novel target discovered using its AI platform. BEN-2293 is a topical PanTrk inhibitor in development to relieve inflammation and rapidly resolve itch in patients with atopic dermatitis.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board FrancoisNader 66 4/1/2022 4/1/2022
Chief Executive Officer, Executive Director JoergMoeller 1/24/2024 1/24/2024
Chief Financial Officer CatherineIsted 48 9/11/2023 9/11/2023
6 additional Officers and Directors records available in full report.

Business Names
Business Name
BAI
ODYSY

General Information
Number of Employees: 248 (As of 12/31/2023)
Outstanding Shares: 121,939,884 (As of 12/31/2023)
Stock Exchange: AMS


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024